US2006147473A1PendingUtilityA1

Mycobacterium cell wall composition

Assignee: CENTENARY INST FOR CANCER MEDIPriority: Nov 13, 1996Filed: Mar 2, 2006Published: Jul 6, 2006
Est. expiryNov 13, 2016(expired)· nominal 20-yr term from priority
A61K 39/04
39
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates generally to a method of immunomodulating therapy and pharmaceutical compositions useful for same. More particularly, the present invention provides a method of ameliorating the effects of autoimmune conditions. Even more particularly, the present invention contemplates a method for preventing, delaying onset of or otherwise ameliorating the effects of insulin-dependant diabetes mellitus (IDDM) by administering a cell wall subunit or a chemical or functional equivalent thereof from Mycobacterium or a related organism or other suitable biological source. The present invention is further directed to a pharmaceutical composition useful in preventing, delaying onset of, curing, curing in association with islet replacement or otherwise ameliorating the effects of autoimmune conditions such as IDDM or for enhancing an immune response against melanoma or other cancer comprising a cell wall subunit or a chemical or functional equivalent thereof from Mycobacterium or a related organism or other suitable biological source. The cell wall subunit is preferably mycolyl-arabinogalactan-peptidoglycan (MAPG) or a component thereof.

Claims

exact text as granted — not AI-modified
1 - 10 . (canceled)  
   
   
       11 . A method for preventing, delaying onset of, curing, curing in association with islet and/or pancreas transplant replacement or otherwise ameliorating the effects of IDDM in a mammal said method comprising administering to said mammal an IDDM treating effective amount of mycolyl arabinogalactan peptidoglycan (MAPG) isolated from the cell wall of  Mycobacterium.    
   
   
       12 . A method according to  claim 11  wherein the mammal is a human.  
   
   
       13 . A method according to  claim 12  wherein the MAPG is administered with one or more of mycolic acid, peptidoglycan or arabinogalactan.  
   
   
       14 . A method according to  claim 13  wherein the MAPG is from  Mycobacterium bovis.    
   
   
       15 - 22 . (canceled)

Join the waitlist — get patent alerts

Track US2006147473A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.